NBIX - Neurocrine Biosciences - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NBIX is currently covered by 25 analysts with an average price target of $146.94. This is a potential upside of $26.76 (22.27%) from yesterday's end of day stock price of $120.18.

Neurocrine Biosciences's activity chart (see below) currently has 315 price targets and 308 ratings on display. The stock rating distribution of NBIX is 27.68% HOLD and 72.32% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 78.82% with an average time for these price targets to be met of 268.32 days.

Highest price target for NBIX is $219, Lowest price target is $115, average price target is $159.25.

Most recent stock forecast was given by DAVID AMSELLEM from PIPER SANDLER on 06-May-2025. First documented stock forecast 04-Feb-2015.

Currently out of the existing stock ratings of NBIX, 31 are a HOLD (27.68%), 81 are a BUY (72.32%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$154

$32.98 (27.25%)

$160

17 days ago
(06-May-2025)

13/16 (81.25%)

$35.08 (29.50%)

375

Buy

$145

$23.98 (19.81%)

$137

17 days ago
(06-May-2025)

17/20 (85%)

$26.08 (21.93%)

117

Buy

$165

$43.98 (36.34%)

$163

17 days ago
(06-May-2025)

1/5 (20%)

$46.08 (38.75%)

43

Buy

$139

$17.98 (14.86%)

$138

17 days ago
(06-May-2025)

0/2 (0%)

$20.08 (16.89%)

Buy

$152

$30.98 (25.60%)

$137

17 days ago
(06-May-2025)

3/7 (42.86%)

$33.08 (27.82%)

262

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NBIX (Neurocrine Biosciences) average time for price targets to be met?

On average it took 268.32 days on average for the stock forecasts to be realized with a an average price target met ratio 78.82

Which analyst has the current highest performing score on NBIX (Neurocrine Biosciences) with a proven track record?

DANIELLE BRILL

Which analyst has the most public recommendations on NBIX (Neurocrine Biosciences)?

Danielle Brill works at RAYMOND JAMES and has 1 price targets and 2 ratings on NBIX

Which analyst is the currently most bullish on NBIX (Neurocrine Biosciences)?

Jay Olson with highest potential upside - $97.98

Which analyst is the currently most reserved on NBIX (Neurocrine Biosciences)?

Thomas Wei with lowest potential downside - -$69.25

Neurocrine Biosciences in the News

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Shareholders of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will be pleased this week, given that the stock price is up 13% to US$122 following its latest first-quarter results. Results overall were not great, with earnings of US$0.08 per share falling drastically short of analyst expectations. Meanwhile revenues hit US$573m and were slightly better than forecasts. Following the...

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

– Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose – Findings to be Presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology SAN DIEGO, May 8, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new results...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?